Ernexa Therapeutics Selected as One of Only Ten Global Companies for Prestigious JETRO Japan Entry Acceleration Program

Ernexa Therapeutics (Nasdaq: ERNA) was selected as one of 10 global companies to join JETRO’s Japan Entry Acceleration Program (JEAP) on Jan 27, 2026, chosen from about 70 regenerative medicine applicants across 25 countries.

Rhea-AI Summary

Ernexa Therapeutics (Nasdaq: ERNA) was selected as one of 10 global companies to join JETRO’s Japan Entry Acceleration Program (JEAP) on Jan 27, 2026, chosen from about 70 regenerative medicine applicants across 25 countries. JEAP provides mentor-led market-entry guidance, connections with Japanese CDMOs and CROs, and targeted support on regulatory, clinical and commercial pathways to accelerate business co-creation in regenerative medicine and oncology. Ernexa said the program will help advance its pipeline in Japan, anchored by two lead cell therapy programs: ERNA-101, entering first-in-human trials in ovarian cancer this year, and ERNA-201, targeting pathogenic inflammation in autoimmune disease.

Positive

• Selected among 10 companies from ~70 JEAP applicants
• ERNA-101 entering first-in-human clinical trials in 2026
• Direct access to Japanese CDMOs and CROs for development
• Expert-led mentoring on Japan regulatory and commercial pathways

Negative

• None.

Argus Jan 27 session

-0.85% close to close Open Argus

Details

News Market Reaction – ERNA

On Jan 27, the day this news came out, ERNA closed 0.85% below the previous close.

Data tracked by StockTitan Argus for the Jan 27 session.

Key Figures

JEAP participants: 10 companies JEAP applicants: approximately 70 companies Oncology-focused cohort: 6 of 10 companies +5 more

JEAP participants

10 companies

Selected global companies in JETRO Japan Entry Acceleration Program

JEAP applicants

approximately 70 companies

Regenerative medicine companies applying from 25 countries

Oncology-focused cohort

6 of 10 companies

JEAP cohort members focusing on oncology

Q3 2025 net loss

$1.24 million

Quarterly loss vs $26.60 million a year ago

Q3 2025 cash

$3.05 million

Cash as of September 30, 2025

Gross proceeds 2025

$7.20 million

Common stock and pre-funded warrant sales in 2025

Operating cash used

$5.87 million

Operating cash usage year-to-date 2025

Shares outstanding

7,848,889 shares

Common shares outstanding as of November 7, 2025

Historical Context

5 past events · Latest: Jan 06

5 events

1. Jan 06

   Regulatory progress

   24h Move

   +5.0%

   FDA Pre-IND meeting secured pathway toward first-in-human ovarian cancer trial.

2. Dec 08

   Clinical data

   24h Move

   -1.5%

   ASH preclinical data for ERNA-101 showing strong immune activation and survival benefit.

3. Dec 03

   Conference presentation

   24h Move

   -4.2%

   Announcement of upcoming ASH oral presentation on iMSC platform tumor microenvironment data.

4. Dec 02

   Advisory appointment

   24h Move

   -4.0%

   Added leading gynecologic oncologist to advisory board to guide ERNA-101 development.

5. Nov 11

   Conference participation

   24h Move

   -5.4%

   Presentations at Cell 2025 on clinical translation, funding, and regulatory strategy for iMSC platform.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

regenerative medicine, oncology, autoimmune disease, first-in-human clinical trials, +2 more

6 terms

regenerative medicine medical

"regenerative medicine companies from 25 countries, underscoring the competitiveness"

A field of medical treatments that aims to repair, replace or regenerate damaged tissues and organs using approaches such as cell or gene therapies, engineered tissues, and biologically active materials. It matters to investors because successful regenerative therapies can create entirely new, high-value markets and replace chronic treatments, offering large potential returns but also long development timelines, heavy regulation and high technical risk—like betting on a promising new technology that could either revolutionize care or fail in trials.

oncology medical

"Japan’s globally recognized regenerative medicine and oncology ecosystem."

Oncology is the branch of medicine focused on understanding, diagnosing, and treating cancer, including the development and testing of drugs, therapies, and screening methods. It matters to investors because advances, trial results, regulatory approvals, or setbacks in cancer research can dramatically change the value of companies and the size of potential markets—think of oncology news as weather reports that help investors steer financial decisions in a high-stakes field.

autoimmune disease medical

"novel cell therapies for the treatment of advanced cancer and autoimmune disease, today"

An autoimmune disease is a condition in which the body's defense system mistakenly attacks its own healthy tissues, like a security team that can't tell residents from intruders, causing inflammation and potential organ damage. For investors, these diseases matter because they create sustained markets for treatments, diagnostics and care, influence the value of research and drug pipelines, and carry regulatory and clinical-trial risks that affect company revenue prospects.

first-in-human clinical trials medical

"The drug candidate is entering first-in-human clinical trials in ovarian cancer this year."

The first-in-human clinical trial is the initial study where an experimental drug or medical device is given to people to check basic safety, how the body processes it, and appropriate dosing; these trials are small and closely monitored. For investors, they are an early high-stakes milestone: clear safety and dosing results can remove major uncertainty and increase a program’s value, while problems can sharply reduce prospects—like a first road test that reveals whether a new product can move forward.

cdmos technical

"development organizations, including CDMOs and CROs, to explore potential collaborations"

Contract Development and Manufacturing Organizations (CDMOs) are independent companies that help drug and biologic developers by designing, testing, scaling up and producing medicines on a contract basis — think of them as a hired factory and research partner that turns a medical idea into a manufacturable product. They matter to investors because they provide steady, service-based revenue, spread development and production risk for drug makers, and their capacity, quality and pricing can directly affect the speed and cost of getting medicines to market.

cros technical

"development organizations, including CDMOs and CROs, to explore potential collaborations"

Contract research organizations (CROs) are independent firms hired by drug and medical-device companies to run research tasks such as clinical trials, patient recruitment, lab testing, data management, and regulatory filings. For investors they matter because CROs act like contractors turning a sponsor’s plans into finished work—so their capacity, timelines, costs and quality directly affect how quickly and cheaply a drug or device can move toward approval and revenue.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

CAMBRIDGE, Mass., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today announced it has been selected as one of only ten companies worldwide to participate in the Japan Entry Acceleration Program (JEAP), a highly competitive initiative launched by the Japan External Trade Organization (JETRO).

JEAP drew approximately 70 regenerative medicine companies from 25 countries, underscoring the competitiveness of the selection process. Ernexa was chosen for its differentiated cell therapy platform and its potential to contribute meaningfully to Japan’s globally recognized regenerative medicine and oncology ecosystem. Notably, six of the ten selected companies focus on oncology, placing Ernexa among an elite group recognized for innovation in one of the world’s most critical and high-value therapeutic areas.

“Japan is a world leader in regenerative medicine, supported by a progressive regulatory framework and deep oncology expertise. Participation in JEAP gives us direct access to key stakeholders as we evaluate strategic partnerships, clinical development opportunities and potential pathways to expand our platform internationally. Our ultimate goal is to deliver hope to patients with cancer and autoimmune conditions worldwide,” said Sanjeev Luther, President and Chief Executive Officer of Ernexa Therapeutics.

As a selected participant, Ernexa will receive expert-led mentoring and market-entry guidance focused on Japan’s regulatory, clinical and commercial landscape. The program also provides direct engagement opportunities with leading Japanese research and development organizations, including CDMOs and CROs, to explore potential collaborations across development, manufacturing and clinical execution.     

The program will help advance Ernexa’s pipeline in Japan. Ernexa’s pipeline is anchored by two lead cell therapy programs. ERNA-101 is being developed to help the immune system better recognize and attack tumors, addressing the profound unmet need in cancers such as ovarian cancer, where effective long-term treatment options remain limited. The drug candidate is entering first-in-human clinical trials in ovarian cancer this year. ERNA-201 is designed to target harmful inflammation at its source in autoimmune disease, with the goal of restoring balance to an overactive immune system rather than broadly suppressing it. Together, these programs exemplify Ernexa’s commitment to advancing next-generation therapies that not only push scientific boundaries but also offer meaningful new hope to patients facing serious, life-altering conditions.

JEAP is JETRO’s first acceleration program for overseas startups and is part of the Japanese government-backed J-Bridge initiative, which aims to attract international investment and foster strategic collaboration between global innovators and Japanese companies. The program focuses on accelerating business co-creation opportunities within the regenerative medicine sector, including oncology.

About Ernexa Therapeutics

Ernexa Therapeutics (NASDAQ: ERNA) is developing innovative cell therapies for the treatment of advanced cancer and autoimmune diseases. Ernexa’s core technology focuses on engineering induced pluripotent stem cells (iPSCs) and transforming them into induced mesenchymal stem cells (iMSCs). Ernexa’s allogeneic synthetic iMSCs provide a scalable, off-the-shelf treatment solution, without needing patient-specific cell harvesting.

ERNA-101 is the company’s lead cell therapy product, designed to activate and regulate the immune system's response to recognize and attack cancer cells. ERNA-201 is a cell therapy product designed to target inflammation and treat autoimmune disease. The company’s initial focus is to develop ERNA-101 for the treatment of ovarian cancer.

For more information, visit www.ernexatx.com.

Media Contact
Sharon Golubchik
RAYNZ
sharon@raynzhealth.com

Investor Contact
Jenene Thomas
JTC Team, LLC
(908) 824-0775
ENRA@jtcir.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Ernexa (ERNA) announce on January 27, 2026 about JEAP?

Ernexa announced selection as one of 10 companies for JETRO’s JEAP, chosen from ~70 regenerative medicine applicants.

How will JEAP participation affect Ernexa’s Japan strategy (ERNA)?

It provides mentor-led market-entry guidance, regulatory insights, and direct engagement with Japanese CDMOs and CROs to explore partnerships.

When will ERNA-101 begin first-in-human trials for ovarian cancer?

ERNA-101 is entering first-in-human clinical trials in 2026 (the release states 'this year').

What programs anchor Ernexa’s pipeline mentioned in the announcement (ERNA)?

Two lead cell therapy programs: ERNA-101 (tumor-targeting, ovarian cancer) and ERNA-201 (targets harmful inflammation in autoimmune disease).

Does JEAP focus specifically on oncology for Ernexa (ERNA)?

Yes; six of the ten JEAP-selected companies focus on oncology, and the program emphasizes regenerative medicine including oncology.